StockDocs
Main Newswire Learn
Project by Matthew Castle Please send feedback to matthewgcastle@gmail.com
GELS

Gelteq Limited

GELS Nasdaq Pharmaceutical Preparations EDGAR ↗
$0.53
-0.02 -2.91%

Key statistics

from XBRL data in SEC filings
Market cap ⓘ
$5.01M
Revenue (TTM) ⓘ
—
Net income (TTM) ⓘ
—
EPS (TTM) ⓘ
—
P/E ratio ⓘ
—
Dividend yield ⓘ
—
Free cash flow ⓘ
—
Cash ⓘ
—
Total assets ⓘ
—
Gross margin ⓘ
—
52-week range ⓘ
$0.39 – $2.01

AI briefing

from the latest 10-K, 10-Q and 8-K events

Gelteq Ltd is an Australia-based pharmaceutical company that develops and commercializes gel-based delivery technologies for nutraceutical and pharmaceutical products.

What they do

Gelteq develops proprietary gelatin-based delivery systems (e.g., gels, gummies) for active ingredients. The company operates primarily in the nutraceutical and pharmaceutical sectors, with a focus on products designed for improved bioavailability and patient compliance. It has not yet generated significant revenue from product sales.

Revenue drivers

  • License and partnership agreements — The company may generate revenue by licensing its gel technology to third-party manufacturers or brands, though no such agreements are described in the provided excerpts.
  • Future product sales — Plans to sell proprietary finished products (e.g., gel-based supplements or pharmaceuticals), but current revenues are immaterial or not disclosed in the filing excerpt.

Recent performance

The filing covers the fiscal year ended June 30, 2025, but the provided excerpts do not include specific revenue or net income figures. The company is listed on Nasdaq under ticker GELS with 10,711,059 ordinary shares outstanding as of November 13, 2025. No operational milestones or financial results are detailed in the available text.

Strategy

The stated strategy focuses on securing intellectual property rights, entering license agreements to protect product use, and avoiding infringement. Management intends to grow through new product development and market expansion, leveraging its proprietary gel technology. The company also aims to manage growth and meet Nasdaq listing requirements.

Risks

  • Nasdaq compliance risk — The company explicitly lists the ability to meet Nasdaq requirements as a forward-looking risk, suggesting potential delisting if not maintained.
  • Intellectual property risk — Ability to secure IP rights and avoid infringing third-party patents is uncertain, which could limit commercialization.
  • Financial viability risk — The company may not generate sufficient cash flows to meet obligations as they become due, given the early stage.
  • Market acceptance risk — Success in new markets is uncertain, and actual results could differ materially from expectations.

Outlook

Management believes the company can achieve positive cash flows and financial viability through operations and new opportunities. The outlook is forward-looking, emphasizing the ability to grow and manage new business ventures. No specific guidance or targets are provided in the excerpts.

Recent SEC filings

40 most recent
Annual, quarterly & current reports
Other filings
SEC STAFF LETTER Apr 4, 2024